Source: Eur Respir Rev 2009; 18: 148-153
Disease area: Pulmonary vascular diseases


For technical reasons, this interactive material needs to open in a new window.
Please allow pop-ups from ers-education.org.
If the window did not open automatically, please click here.

Rating:

Share or cite this content

Citations should be made in the following way:
Galie N., Negro L., Simonneau G.. The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 2009; 18: 148-153

Member's Comments

No comment yet.

Related content which might interest you: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Source: Eur Respir J 2003; 22: 330-334 Year: 2003 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007